Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Swedish Orphan Biovitrum AB Sobi
Swedish Orphan Biovitrum AB Sobi
Activities:
Manufacturing
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Ingredients
Therapeutic: efanesoctocog alfa for haemophilia A
Haemophilia A is a rare genetic disorder in which the blood cannot clot properly; this is caused by a lack of factor VIII, one of the proteins involved in the clotting cascade
Recruitment
Sobi appoints Head of Technical Operations
Research & Development
Sobi Orfadin capsules approved in Saudi Arabia
Swedish Orphan Biovitrum's orfadin capsules approved in the Kingdom of Saudi Arabia for the treatment of hereditary tyrosinemia type 1
Estates & Facilities
Sobi opens office in Greece
The company is welcomed by those hoping for innovative therapeutic solutions in Greece
Regulatory
Sobi’s Elocta approved in Switzerland for the treatment of haemophilia A
Elocta is indicated for both on-demand and prophylaxis treatment of people with haemophilia A of all ages
Manufacturing
Sobi signs manufacturing agreements with Pfizer
Sobi is dedicated to developing and delivering innovative therapies for rare diseases
Chief Medical Officer Birgitte Volck to leave Sobi
To join GlaxoSmithKline as Head of R&D Rare Diseases
Subscribe now